Trial reportMenopause (New York, N.Y.)2012
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Trial report in Menopause (New York, N.Y.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Menopause Strategies: Finding Lasting Answers for Symptoms and Health: Efficacy of a Selective Serotonin Reuptake Inhibitor (SSRI) for Menopausal Symptoms in Midlife Women
Pilot Study to Assess Tolerability and Preliminary Efficacy of a Titrated Dose of Gabapentin up to 600mg Administered at Bedtime for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women With VMS.
A Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's Disease
Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials.Iranian journal of medical sciences · 2022Pooled it
- SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials.Journal of general internal medicine · 2014Pooled it
- Efficacy and Safety of Hormone Replacement Combined With Escitalopram in the Treatment of Chronic Insomnia in Perimenopausal Women: A Randomized Controlled Trial.CNS neuroscience & therapeutics · 2025Trial
- Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial.Archives of gynecology and obstetrics · 2022Trial
- Effect of Hypnosis on Anxiety: Results from a Randomized Controlled Trial with Women in Postmenopause.Journal of clinical psychology in medical settings · 2021Trial
- The Effectiveness of Melissa Officinalis L. versus Citalopram on Quality of Life of Menopausal Women with Sleep Disorder: A Randomized Double-Blind Clinical Trial.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2021Trial
- Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS).Menopause (New York, N.Y.) · 2018Trial
- Trial
- Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms: A MsFLASH Randomized Clinical Trial.JAMA internal medicine · 2016Trial
- Trial
- Trial
- North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes.Menopause (New York, N.Y.) · 2015Trial
- Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause.Menopause (New York, N.Y.) · 2015Trial
- MsFLASH participants' priorities for alleviating menopausal symptoms.Climacteric : the journal of the International Menopause Society · 2015Trial
- Effects of estradiol and venlafaxine on insomnia symptoms and sleep quality in women with hot flashes.Sleep · 2015Trial
- Increases in duration of first uninterrupted sleep period are associated with improvements in PSQI-measured sleep quality.Sleep medicine · 2014Trial
- Trial
- Insomnia in Postmenopausal Women: How to Approach and Treat It?Journal of clinical medicine · 2024Review
- A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms.International journal of women's health · 2022Review
- Contemporary Non-hormonal Therapies for the Management of Vasomotor Symptoms Associated with Menopause: A Literature Review.TouchREVIEWS in endocrinology · 2021Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
Abstract
objectiveThe aim of this study was to determine the effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes.
methodsA randomized, blinded, multicenter, placebo-controlled parallel-group 8-week trial with 205 women (95 African American, 102 white, 8 other) was conducted between July 2009 and June 2010. The participants received escitalopram (10-20 mg/d) or placebo. Insomnia symptoms (Insomnia Severity Index [ISI]) and subjective sleep quality (Pittsburgh Sleep Quality Index [PSQI]) at weeks 4 and 8 were the prespecified secondary outcomes. A total of 199 women (97%) provided ISI data, and 194 (95%) women provided PSQI data at follow-up.
resultsAt baseline, mean hot flash frequency was 9.78 per day (SD, 5.60), mean ISI was 11.4 (SD, 6.3), and mean PSQI was 8.0 (SD, 3.7). Treatment with escitalopram reduced ISI at week 8 (mean difference, -2.00; 95% CI, -3.43 to -0.57; P < 0.001 overall treatment effect), with mean differences of -4.73 (95% CI, -5.72 to -3.75) in the escitalopram group and -2.73 (95% CI, -3.78 to -1.69) in the placebo group. The reduction in PSQI was greater in the escitalopram than in the placebo group at week 8 (mean difference, -1.31; 95% CI, -2.14 to -0.49; P < 0.001 overall treatment effect). Clinical improvement in insomnia symptoms and subjective sleep quality (≥50% decreases in ISI and PSQI from baseline) was observed more frequently in the escitalopram group than in the placebo group (ISI, 50.0% vs 35.4%, P = 0.04; PSQI, 29.6% vs 19.2%, P = 0.09).
conclusionsAmong healthy perimenopausal and postmenopausal women with hot flashes, escitalopram at 10 to 20 mg/day compared with placebo reduced insomnia symptoms and improved subjective sleep quality at 8 weeks of follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.